新辅助化疗联合改良根治术治疗的乳腺癌患者术后无病生存期的影响因素

doi:10.3969/j.issn.1671-7171.2024.04.015

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1159 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨新辅助化疗联合改良根治术治疗的乳腺癌患者术后无病生存期的影响因素。【方法】本院收治的150例均接受改良根治术联合新辅助化疗的乳腺癌患者,均接受为期3年的随访,以患者肿瘤转移、复发或死亡为终点,无病生存期＜3年的患者为预后不良组(n=29),无病生存期≥3年的为预后良好组(n=121)。收集两组患者一般资料,并采用单因素、多因素分析影响患者无病生存期的影响因素。【结果】随访3年,150例患者中,死亡16例,总生存率为89.33%(134/150), 复发者6例,转移7例,无病生存率为80.67%(121/150)。预后不良组患者年龄≤45岁占比、月经状态为未绝经占比、肿瘤直径＞5 cm占比、临床分期为T₃及T₄占比、脉管瘤栓阳性占比、术后无放疗占比、雌激素受体(ER )/孕激素受体(PR)为阴性占比、Ki67指数＞30％占比明显高于预后良好组(P<0.05);经多因素Logistic回归分析证实,上述因素均是影响患者术后无病生存期的危险因素(P<0.05)。【结论】年龄≤45岁、月经状态为未绝经、肿瘤直径＞5 cm、临床分期为T₃及T₄、脉管瘤栓阳性、术后无放疗、ER/PR为阴性、Ki67指数＞30％均是影响新辅助化疗联合乳腺癌改良根治术患者术后无病生存期的危险因素。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：乳腺肿瘤/外科学, 化学疗法, 辅助, 无病生存

Abstract：【Objective】To explore the factors influencing disease-free survival in breast cancer patients treated with neoadjuvant chemotherapy combined with modified radical mastectomy.【Methods】A total of 150 breast cancer patients treated in our hospital, who underwent modified radical mastectomy combined with neoadjuvant chemotherapy, were followed up for 3 years. The endpoint of follow-up was tumor metastasis, recurrence, or death. Patients with disease-free survival of less than 3 years were classified as the poor prognosis group (n=29), while those with disease-free survival of 3 years or more were classified as the good prognosis group (n=121). General data of the two groups were collected, and univariate and multivariate analyses were used to identify factors influencing disease-free survival. 【Results】 During the 3-year follow-up of 150 patients, 16 deaths were recorded, giving an overall survival rate of 89.33%(134/150). There were 6 cases of recurrence and 7 cases of metastasis, resulting in a disease-free survival rate of 80.67%(121/150). The proportion of patients aged ≤45 years, premenopausal status, tumor size >5 cm, clinical stage T₃ or T₄, positive vascular tumor embolvs, absence of postoperative radiotherapy, negative estrogen receptor (ER)/progesterone receptor (PR) status, and Ki67 index>30% were significantly higher in the poor prognosis group compared to the good prognosis group (P<0.05). Multivariate logistic regression analysis confirmed that these factors above were risk factors affecting postoperative disease-free survival (P<0.05). 【Conclusion】 Age ≤45 years, premenopausal status, tumor size >5 cm, clinical stage T₃ or T₄, positive vascular tumor thrombus, absence of postoperative radiotherapy, negative ER/PR status, and Ki67 index >30% are risk factors affecting disease-free survival in breast cancer patients treated with neoadjuvant chemotherapy combined with modified radical mastectomy.

Key words： Breast Neoplasms/SU Chemotherapy,Adjuvant Disease-Free Survival

收稿日期: 2022-11-17

中图分类号:

R737.9

通讯作者: ^*E-mail:13152050538@163.com

引用本文:

田博, 盖中仁, 白戈, 潘科年, 陈明溪. 新辅助化疗联合改良根治术治疗的乳腺癌患者术后无病生存期的影响因素[J]. 医学临床研究, 2024, 41(4): 533-536.
TIAN Bo, GAI Zhongren, Bai Ge, et al. Factors Influencing Disease-Free Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy Combined with Modified Radical Mastectomy. JOURNAL OF CLINICAL RESEARCH, 2024, 41(4): 533-536.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2024.04.015 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2024/V41/I4/533

[1] SULAK M, AHISKALIOGLU A, YAYIK A, et al. The effect of ultrasound-guided serratus plane block on the quality of life in patients undergoing modified radical mastectomy and axillary lymph node dissection: a randomized controlled study[J].Anaesthesiol Intensive Ther,2022,54(1):48-55.
[2] XIE X, LI H, WANG C, et al. Effect of modified radical mastectomy combined with neo-adjuvant chemotherapy on postoperative recurrence rate, negative emotion, and life quality of patients with breast cancer[J].Am J Transl Res,2022,14(1):460-467.
[3] 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2011版)[J].中国癌症杂志,2011,21(5):367-417.
[4] GROVA M M, STRASSLE P D, NAVAJAS E E, et al. The prognostic value of axillary staging following neoadjuvant chemotherapy in inflammatory breast cancer[J].Ann Surg Oncol,2021,28(4):2182-2190.
[5] BUSBAIT S, ALKHALIFA A M, ALJOHANI S, et al. Occult invasive lobular carcinoma presenting as an axillary skin metastatic lesion underwent neoadjuvant endocrine therapy and surgical resection: a case report and review of literature[J].Breast Cancer (Dove Med Press),2022,14(1):145-152.
[6] 黄州,王淑莲,唐玉,等. 乳腺癌新辅助化疗后改良根治术后放疗开始时间对预后的影响[J].中华放射肿瘤学杂志,2019,28(4):280-285.
[7] 梁国刚,高薇丽,王群先,等. 208例T1~2N1M0期乳腺癌改良根治术患者无病生存情况的危险因素分析[J].中华普外科手术学杂志(电子版),2020,14(6):604-607.
[8] 陈勇,李娟,麻丽珍. 乳腺癌改良根治术术中行胸肌间淋巴结清扫术对患者近远期临床预后的影响[J].海南医学,2017,28(3):399-401.
[9] 李福平,王茂,刘超,等. 保留乳头乳晕复合体的乳腺癌改良根治术预后的相关因素分析[J].中华普外科手术学杂志(电子版),2020,14(6):608-611.
[10] 荣庆林,王淑莲,唐玉,等. 临床T1~3N1M0期乳腺癌新辅助化疗和改良根治术后腋窝淋巴结病理阴性患者术后放疗的价值[J].中华肿瘤杂志,2017,39(6):445-452.
[11] 穆凌光,孟少华,范秀廷,等. 乳腺癌改良根治术患者术后复发转移的多因素分析[J].现代肿瘤医学,2018,26(17):2706-2710.
[12] 张锋,张卓,邹丽娟,等. 早期三阴乳腺癌改良根治术后放疗及预后相关因素分析[J].中华放射医学与防护杂志,2018,38(7):510-516.
[13] 邵水丰,葛明华. 乳腺癌患者化疗相关粒细胞减少和ER/PR阳性与预后的关系分析[J].中国妇幼保健,2021,36(21):4899-4902.
[14] 李明. 三阴性乳腺癌患者癌组织中雄激素受体、Ki67的表达及与预后的关系[J].中国综合临床,2022,38(2):164-169.
[15] 黄风琴,余洁,郭智俊,等. 乳腺癌EGFR、Ki-67、CerbB-2表达的临床价值与预后[J].分子诊断与治疗杂志,2022,14(5):764-768.